EML4 and non-small cell lung carcinoma: There have been many excellent review articles that summarise the oncogenic signalling pathways activated in NSCLC by the EML4-ALK fusion proteins as well as the mechanisms of action of ALK inhibitors and acquired resistance to these inhibitors e.g., [10,30,62,63].